Fujifilm expands fill/finish services for gene therapies in Texas

By Flora Southey contact

- Last updated on GMT

(Image: Getty/gustavofrazao)
(Image: Getty/gustavofrazao)
Fujifilm Diosynth Biotechnologies has added fill/finish capabilities for late-phase and commercial supply of gene therapies and viral vaccines.

The Japanese contract development and manufacturing organisation (CDMO) has invested in Vanrx Pharmasystems’ SA25 Aseptic Filling Workcell technology to offer “end to end” ​manufacturing services at its flexible manufacturing facility (FBF) in Texas, US.

The 80,000 square-foot plant in College Station – acquired from Kalon Therpaeutics in 2014​ – opened in January this year​.

The fill/finish investment will enable clients to “swiftly”​ advance therapies from bulk drug substance into commercial production, said COO Gerry Farrell in a statement.

“We recognised that having Fill Finish capabilities that extend beyond the current clinical stage is essential to support the rapid delivery of clinical candidates to patients," ​he added.

The announcement is the latest in a line of bioprocessing investments for Fujifilm Corporation, which acquired Diosynth Biotechnologies from Merck & Co. in 2011.

In April last year, the firm said​ it would spend ¥3bn ($27.4m) on mammalian cell culture bioreactors at its Texas-based FBF. The company also announced plans to build a ¥1bn process development facility at its facility in Billingham, UK.

Additionally, in March​ this year, Fujifilm paid $800m (€650m) for cell culture media firm Irvine Scientific.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us

Products

View more

Webinars